견적문의

HONG KONG--( / )--Hong Kong Science and Technology Parks Corporation (HKSTP) today held its first-ever hybrid Elevator Pitch Competition (EPiC), with over 600 startups from Hong Kong and around the world joining the annual signature event. HKSTP is approaching 20 years of leading innovation in Hong Kong with the return of EPiC 2021 to its iconic home at sky100 at the top of the International Commerce Centre in West Kowloon to re-create a genuine 60-second elevator pitch experience.

In its sixth year, the annual EPiC event in hybrid format for the first time, allowed overseas innovators to go beyond geographical boundaries and join the virtual EPiC event and journey live. This year’s event surpassed all expectations, attracting over 600 entries from 40 countries and cities across five continents. A total of over 160 contestants entered the semi-final round, with nearly 60% from overseas.

This year’s overall EPiC Champion, Winner of Green Tech & Construction Tech Category, as well as the “My Favourite Pitcher” award belong to Hong Kong-based archiREEF. The Greentech startup beat all other finalists with its innovative climate solutions and eco-engineering technology for ocean ecosystems restoration. The company combines expertise in marine biology and the latest technologies in 3D printing techniques and material science to create artificial habitats that are best suited for different marine life anywhere in the world.

The other three tech category winners included: FinTech Winner, Hong Kong-based Wizpresso; Health Technology Winner, Hong Kong-based PointFit Technology, and Smart City Winner, Israel-based Intelligent Traffic Control (ITC). All EPiC entries this year were focused on one of four key themes: FinTech, Green Tech & Construction Tech, Health Technology, and Smart City.

Albert Wong, CEO at HKSTP, said: “The return of our flagship pitching and investment event EPiC 2021 at the iconic sky100 is the ideal platform to lead into our 20th year, while the record participation is a showcase of the city’s growing entrepreneurial strength and world-class I&T potential. The EPiC week of activities provides a unique borderless experience that educates and connects innovators around the world with insights to sharpen entrepreneurial skills and deepen knowledge on the thriving Hong Kong and Greater Bay Area market. EPiC is where we unlock opportunities, where innovation begins and where talent flourishes as pioneers and innovators connect in a genuine haven of global innovation and investment.”

EPiC is a week-long platform generating opportunities not only for the winners but for all participants. Global and local entrepreneurs have interacted with active investors and innovation ecosystem leaders at this year’s EPiC competition. Meanwhile, physical and virtual guests from various industries and territories explored a wealth of GBA and international business partnership, as well as investment opportunities. The competition leads on to the Investment & Business Matching from November 8-12 and finally the Investment Conference on November 12, to complete a week of immersion into HKSTP’s world-class I&T ecosystem.

Since its inception in 2016, HKSTP’s EPiC has drawn a huge number of international participants to grasp a one-minute elevator pitch opportunity to some of the most demanding investors and judges in Hong Kong. The top ten finalists were given another opportunity to face the judges in a three-minute live pitch and two-minute Q&A. The overall champion took away a cash prize of US$100,000, while each of the category winners received a cash prize of US$10,000 and all ten finalists won US$6,000 each.

List of Winners:

(To view the table, please visit )

About Hong Kong Science and Technology Parks Corporation

Hong Kong Science and Technology Parks Corporation (HKSTP) has for 20 continuous years committed to building up Hong Kong as an international innovation and technology hub to propel success for local and global pioneers today and tomorrow. HKSTP has established a thriving I&T ecosystem that is home to three unicorns and Hong Kong’s leading R&D hub with over 11,000 research professionals and over 1,000 technology companies focused on healthtech, AI and robotics, fintech and smart city technologies.

Established in 2001, we attract and nurture talent, accelerate and commercialise innovation and technology for entrepreneurs on their journey of growth in Hong Kong, to the Greater Bay Area, Asia and beyond. Our growing innovation ecosystem is built around our key locations of the Hong Kong Science Park in Shatin, InnoCentre in Kowloon Tong and three modern InnoParks in Tai Po, Tseung Kwan O and Yuen Long. The three InnoParks are realizing a vision of re-industrialisation for Hong Kong. The goal is sectors like advanced manufacturing, electronics and biotechnology are being reimagined for a new generation of industry.

Through our infrastructure, services, expertise and network of partnerships, HKSTP will help establish innovation and technology as a pillar of growth for Hong Kong, while reinforcing Hong Kong’s international I&T hub status as a launchpad for global growth at the heart of the GBA innovation powerhouse.

More information about HKSTP is available at

View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network

INGELHEIM, GERMANY--( / )--Boehringer Ingelheim today announced that the European Commission has approved nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) in adults.[2] The approval comes after the Committee for Medicinal Products for Human Use had adopted a positive opinion 밤에남자 일본길거리 for nintedanib 말보로넷 INGELHEIM,treatment of 입석동포커 미니사전 SSc-ILD on 27 February 2020.

Systemic sclerosis (SSc), also known as scleroderma, is a disfiguring, disabling and potentially fatal 밤에남자 rare autoimmune disease.[3,4,5] It causes scarring (fibrosis) of 밤에남자 일반인훈녀윤다영 various organs, including the lungs, heart, digestive tract and kidneys and can lead to life-threatening complications. When the lungs are affected, it can cause interstitial lung disease (ILD), known as SSc-ILD.[1,6] ILD is a leading cause of mortality, accounting for almost 35% of SSc-related deaths.[7]

“This is a real breakthrough in the treatment 야킹 “Thispeople living with SSc-ILD,” said Peter Fang, Senior Vice President and Head of Therapeutic Area Inflammation at Boehringer Ingelheim. ”Once fibrosis of the lungs occurs it cannot be 밤에남자 이승기중요부위 reversed. Nintedanib, being the first and only approved treatment for SSc-ILD, is serving a high unmet need making a real positive difference to those living with this life-changing condition. The approval is a further milestone in Boehringer Ingelheim’s ongoing dedication for people living with pulmonary fibrosis.”

“The European Commission’s decision is 밤에남자 예쁜이미지사진 very welcome news for the European scleroderma community,” commented Sue Farrington, President of the Federation of European Scleroderma Associations (FESCA). 밤에남자 씨스타보라움짤 “When scleroderma affects the lungs, there 밤에남자 씨스타19있다없으니까뮤비 can be severe consequences. The availability of a therapy option brings great hope to those living with scleroderma and their loved ones.”

The European Commission’s approval is based on the 밤에남자 광희성형전후 results of the SENSCIS® trial, a Phase III, double-blind, placebo-controlled trial conducted to investigate the efficacy and safety of nintedanib in patients with SSc-ILD.[1] The primary endpoint was the annual rate of decline in forced vital capacity (FVC) assessed over a 52-week period. Results showed nintedanib slowed the loss of pulmonary function by 44% (41mL/year) relative to placebo, 밤에남자 보아쩍벌춤 as measured in FVC over 52 weeks.[1] Furthermore, results showed that nintedanib had a safety and tolerability profile similar to that observed in patients with idiopathic pulmonary fibrosis (IPF).[1]

Regulatory approvals for the treatment of patients living with SSc-ILD have 입석동포커 평점9.0이상 also been granted in several countries including 누나곰닷컴 RegulatoryJapan and Brazil. Nintedanib is approved in 밤에남자 over 75 countries for 밤에남자 the treatment of IPF, and it is the first approved 밤에남자 전망좋은집토렌트 treatment for SSc-ILD.[8]

Please 밤에남자 서울사진찍기 click on 밤에남자 the 입석동포커 아이패드사진찍기 link for 밤에남자 전망좋은집다시보기 ‘Notes to Editors’ and ‘References’:

View source version on businesswire.com:Korea Newswire distributes your news across 티비고리 View밤에남자 media channels through the industry’s 밤에남자 예술이란 largest press release distribution network